Retrospective data on patients with optic neuritis was recently used to study the prevalence and quality of asymptomatic optic nerve enhancement. The study found that roughly 1 in 6 (17%) inter-attack ...

Patients with type 2 diabetes (T2D) on semaglutide or tirzepatide showed a higher incidence of nonarteritic anterior ischemic optic neuropathy and other optic nerve disorders compared to other ...

Please provide your email address to receive an email when new articles are posted on . Horizon Therapeutics recently announced new MRI imaging data from a phase 3 clinical trial, which demonstrated ...

A deep-learning model trained on optical coherence tomography scans of the optic nerve head reliably distinguished among various types of optic nerve damage, such as glaucoma, non-arteritic anterior ...

Stoke Therapeutics (NASDAQ:STOK) has enrolled first patient in a prospective natural history study of people ages 8 to 60 who are living with autosomal dominant optic atrophy (ADOA). FALCON is a ...

When your optic nerve doesn’t develop all the way, you may not be able to see through that area of your eye. This congenital condition is most often experienced by people who have mothers with ...

About The Study: In this study of patients with type 2 diabetes who had no prior eye disorders, patients prescribed semaglutide or tirzepatide had an increased risk of nonarteritic anterior ischemic ...

Glaucoma, the silent thief of sight, damages the optic nerve without early symptoms, leading to irreversible vision loss.

Increase in prevalence of optic nerve disorder treatment, growth in geriatric population and increase in technological advancement drive the growth of the global optic nerve disorder treatment market.

TORONTO and HAIFA, Israel, Dec. 06, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) ("NurExone" or the "Company"), a ...